If a blood test came back flagging your liver, or a doctor just used the words "alcohol-associated liver disease," you're probably trying to figure out what that actually means for you or someone you love. How serious is this? What's already done? What can still be turned around? Those are exactly the right questions — and the answers depend heavily on which stage you're dealing with.

Alcoholic liver disease (ALD) isn't a single condition. It's a spectrum that moves through recognizable stages, and where someone is on that spectrum determines what's reversible, what treatment looks like, and what happens next. The good news is that the earlier it's caught, the more options exist. The harder truth is that most people don't find out until the disease is already advanced.

What the research makes unmistakably clear is this: treating the liver without treating the drinking that damaged it is a strategy that doesn't work. The two have to be addressed together.

What are the stages of alcoholic liver disease — and what's still reversible?

ALD progresses through a recognizable sequence. Understanding where someone falls on this spectrum is the first step toward knowing what treatment can realistically accomplish.

• Steatosis (fatty liver). Fat accumulates in liver cells in response to alcohol metabolism. This is the earliest and most common stage, present in up to 90% of heavy drinkers. It's also the most reversible — stopping drinking allows the liver to clear the fat. No medication reverses steatosis; abstinence does [görgülü-2026-acute-changes-liver].

• Steatohepatitis. Inflammation is added to fat accumulation. Under a microscope, you'd see swollen liver cells, lobular inflammation, and early scarring. This stage is still potentially reversible but carries real risk of progression if drinking continues.

• Fibrosis. The liver scars in response to repeated injury. Fibrosis is staged F1 through F4. As it advances, the liver's normal structure is progressively replaced by scar tissue. Stages F3–F4 are the threshold where serious complications become likely.

• Cirrhosis. End-stage fibrosis — the liver's architecture is replaced by scar tissue and abnormal regenerative nodules. About 75% of people with cirrhosis don't know they have it until an emergency brings them to the hospital [1]✓ Verified knowledgeArab et al. (2023) — Alcohol associated liver. This is the stage where most people first encounter the medical system.

• Decompensation. The transition from "compensated" (functioning despite damage) to clinically overt liver failure: fluid buildup in the abdomen (ascites), bleeding from enlarged veins in the esophagus (varices), confusion from toxin buildup (hepatic encephalopathy), and jaundice. Each decompensation event worsens the overall prognosis.

• Acute alcoholic hepatitis. A distinct, superimposed crisis — rapid-onset jaundice, liver enlargement, fever, and elevated white blood cell count — that can occur at any stage of underlying ALD. In its severe form, it carries a 30-day mortality of 30–50% [2]✓ Verified knowledgeLee et al. (2024) — Designing clinical trials.

• Hepatocellular carcinoma (HCC). Liver cancer is a late complication of alcoholic cirrhosis. Critically, the risk persists even after someone achieves sustained sobriety once cirrhosis is established — which is why surveillance continues regardless of abstinence status.

The stage at which ALD is caught is the single biggest determinant of what's still possible. Earlier is always better.

How does a doctor know what stage you're at?

Most people with ALD are identified too late — but that's changing as non-invasive testing improves. Earlier detection in people with alcohol use disorder is associated with higher rates of sustained abstinence at one year [3]✓ Verified knowledgeOrgill et al. (2024) — Early detection liver.

Lab markers are usually the first signal. An AST:ALT ratio greater than 2:1 is a classic pattern in alcohol-related liver injury. Elevated GGT (gamma-glutamyl transferase) is a sensitive — though not highly specific — marker of heavy alcohol use and liver inflammation. These tests are inexpensive and available in any primary care office.

Phosphatidylethanol (PEth) is a more precise alcohol biomarker — a compound that forms in red blood cell membranes only when ethanol is present. It reflects drinking over the preceding 3–4 weeks and is substantially more specific than GGT. Integrated ALD clinics use PEth to monitor abstinence over time.

Non-invasive fibrosis tools have transformed staging. The FIB-4 index (calculated from age, AST, ALT, and platelet count) and the APRI score provide validated fibrosis risk estimates from routine bloodwork. Transient elastography (FibroScan) measures liver stiffness in kilopascals and reliably stages fibrosis across the full spectrum — allowing hepatologists to identify who needs closer monitoring without subjecting everyone to a biopsy.

Liver biopsy remains the gold standard when non-invasive tests give conflicting results or when the distinction between alcoholic hepatitis and another cause of acute liver injury has direct treatment implications.

What happens during acute alcoholic hepatitis — and how is it treated?

Acute alcoholic hepatitis is the most immediately dangerous presentation on the ALD spectrum. It can develop rapidly — often within weeks of a heavy drinking episode — and it demands fast recognition.

Recognizing and scoring severity

The syndrome looks like: sudden-onset jaundice (bilirubin typically above 3 mg/dL), a tender, enlarged liver, fever, and an elevated white blood cell count. Ascites and confusion may also be present. The clinical picture can mimic serious infection — and the two frequently coexist.

Three scoring tools form the prognostic framework:

What the evidence supports for treatment

The STOPAH trial (2015) remains the landmark study for pharmacological management of severe alcoholic hepatitis. Prednisolone (40 mg/day for 28 days) reduced 28-day mortality modestly but significantly — but this short-term benefit did not translate into sustained improvement at 90 days or one year. That finding underscores a hard truth: anti-inflammatory therapy has real limits when the alcohol use disorder driving the disease goes untreated.

The ACG 2024 Clinical Guideline [2]✓ Verified knowledgeLee et al. (2024) — Designing clinical trials supports corticosteroids for severe AH (Maddrey ≥32), with the Lille score at day 7 used to identify non-responders who should stop steroids. Pentoxifylline is no longer recommended — it doesn't add benefit. N-acetylcysteine combined with corticosteroids may reduce early infection risk. G-CSF is under active investigation as a regenerative therapy but isn't yet standard of care.

No pharmacological treatment for acute alcoholic hepatitis addresses the alcohol use disorder that caused it. Patients who survive a severe episode and return to drinking face near-certain disease progression [1]✓ Verified knowledgeArab et al. (2023) — Alcohol associated liver.

How is cirrhosis managed once it's established?

Once alcoholic cirrhosis is present, treatment shifts to preventing and managing the complications of portal hypertension and liver failure. The major complications each have specific management approaches:

• Hepatic encephalopathy — the confusion and cognitive changes caused by toxin buildup — is treated with lactulose (titrated to 2–3 soft stools per day) and rifaximin (550 mg twice daily) for prevention of recurrent episodes. Identifying triggers like infection, GI bleeding, or constipation is essential. The effects of heavy alcohol use on the brain are relevant here — encephalopathy compounds existing alcohol-related neurological changes.

• Ascites is managed with sodium restriction and diuretics (typically spironolactone with or without furosemide). When ascites becomes refractory, large-volume paracentesis with albumin replacement is needed. A TIPS procedure (transjugular intrahepatic portosystemic shunt) is considered for appropriate candidates.

• Variceal bleeding is a life-threatening emergency managed acutely with octreotide, antibiotics, and endoscopic variceal ligation. Non-selective beta-blockers (propranolol, carvedilol) are the cornerstone of prevention. Endoscopic band ligation is used for primary prophylaxis in patients with high-risk varices.

• HCC surveillance — liver ultrasound every 6 months, with or without AFP — is recommended for all patients with cirrhosis, regardless of whether they've stopped drinking. The cancer risk doesn't disappear with sobriety once cirrhosis is established.

Through all of this, abstinence remains the single most powerful modifier of prognosis — reducing decompensation risk, improving liver function scores, and in some patients allowing partial reversal of fibrosis [görgülü-2026-acute-changes-liver].

What about liver transplantation?

The six-month rule — and why it's being challenged

For decades, most transplant programs required six months of documented abstinence before listing someone with alcoholic liver disease. The rationale was twofold: to allow the liver time to recover on its own (potentially avoiding transplant altogether) and to use sustained sobriety as a proxy for post-transplant behavior.

That rule is now being actively challenged. Early liver transplantation for severe alcoholic hepatitis — listing carefully selected patients without the six-month requirement — has growing evidence behind it [1]✓ Verified knowledgeArab et al. (2023) — Alcohol associated liver [görgülü-2026-acute-changes-liver]. Patients who meet rigorous psychosocial criteria and haven't responded to medical therapy have shown post-transplant outcomes comparable to those transplanted for other indications.

The tension is real and unresolved. Proponents of early transplant argue the six-month rule was never evidence-based and denies a life-saving intervention to people who could benefit. Those who defend it argue that psychosocial readiness can't be adequately assessed in an acute crisis. Both positions have merit, and the field hasn't reached consensus.

Why AUD treatment before and after transplant matters

Post-transplant alcohol relapse occurs in roughly 20–25% of the general ALD transplant population. But here's what the data show clearly: AUD treatment in liver transplant recipients reduces post-transplant alcohol relapse by 59% and mortality by 56% in observational studies [4]✓ Verified knowledgePrasad et al. (2025) — Pharmacological therapies alcohol [5]✓ Verified knowledgeElfeki et al. (2023) — Simultaneous management alcohol.

Among 1,309 patients with severe ALD referred for transplant evaluation, medications for alcohol use disorder used for at least three months were associated with 6.6% higher one-year survival and 18.5% higher three-year survival (HR 0.59, 95% CI 0.39–0.92), independent of MELD score and transplant status [6]✓ Verified knowledgeJophlin et al. (2024) — Acg clinical guideline. This is the strongest evidence in the literature that pharmacotherapy benefits the sickest patients — and it's precisely this population where prescribing rates are lowest.

Failing to initiate AUD treatment before transplant isn't just a pre-transplant care gap. It's a post-transplant outcomes failure.

Which medications help with alcohol use disorder in people with liver disease?

This is where a critical misconception needs to be addressed directly: clinician hesitancy about prescribing AUD medications to people with liver disease is largely not supported by the pharmacological evidence [7]✓ Verified knowledgeHaque et al. (2024) — Integrated collaborative care. The ACG 2024 guideline recommends pharmacotherapy for AUD in ALD patients [2]✓ Verified knowledgeLee et al. (2024) — Designing clinical trials, and the mortality benefit of doing so is documented [8]✓ Verified knowledgeHarris et al. (2026) — Impact pharmacologic treatment.

A meta-analysis of 25 studies involving nearly 94,000 patients found that any AUD treatment reduced alcohol relapse by 73%, and medications specifically reduced relapse by 77% across five RCTs [4]✓ Verified knowledgePrasad et al. (2025) — Pharmacological therapies alcohol. AUD treatment was also associated with a 48% reduction in readmission and a 52% reduction in decompensation.

Here's how the main medications compare in the context of liver disease:

The barriers to prescribing these medications in ALD patients are documented as clinician-level (lack of training, discomfort managing AUD) and system-level (insurance structures, organizational disincentives) — not evidence-based pharmacological contraindications [7]✓ Verified knowledgeHaque et al. (2024) — Integrated collaborative care.

If you or someone you love is navigating alcohol detox or managing withdrawal symptoms alongside liver disease, the medication picture becomes even more important to discuss with a physician who understands both conditions.

Why does treating the drinking matter as much as treating the liver?

This is the central message: in alcoholic liver disease, abstinence is the survival intervention. Everything else — corticosteroids, diuretics, rifaximin, transplant — supports or extends life. Stopping drinking is what changes its trajectory.

AUD pharmacotherapy doesn't replace abstinence. It supports it. The 77% reduction in relapse with medications [4]✓ Verified knowledgePrasad et al. (2025) — Pharmacological therapies alcohol is a reduction in the risk of the event that kills people with ALD. Framing these medications as optional adjuncts misunderstands their role: they're the mechanism by which sustained sobriety becomes achievable for people whose biology and psychology make it genuinely difficult without support.

The ACG 2024 guideline is explicit: multidisciplinary integrated care — hepatology, addiction medicine, social work, and psychology working together — is the standard of care for ALD [2]✓ Verified knowledgeLee et al. (2024) — Designing clinical trials. Treating liver disease in isolation, without addressing the alcohol use disorder driving it, "will inevitably lead to failure because transient improvements in liver function are rapidly overturned if the patient returns to alcohol consumption" [1]✓ Verified knowledgeArab et al. (2023) — Alcohol associated liver.

The data from integrated ALD clinics back this up. One multidisciplinary clinic saw the proportion of patients with active severe AUD drop from 85.2% to 51.9%, with significant reductions in liver inflammation markers and emergency department visits [11]✓ Verified knowledgeSengupta et al. (2025) — Impact integrated care. Another reported that 57% of patients were prescribed relapse-prevention medications after joint assessment, with reduced hospital utilization and improved liver function scores [12]✓ Verified knowledgeMellinger et al. (2021) — Feasibility early experience.

The hospitalization is the leverage point

Among 417 ALD/AUD admissions at one institution: 16% attended hepatology follow-up within 90 days, 4% were referred to substance use services, and 14% received an AUD medication prescription at discharge [13]✓ Verified knowledgeAsrani et al. (2021) — Reducing global burden. Those numbers represent near-complete treatment failure at the system level.

But a brief intervention on alcohol use disorder delivered during that hospitalization had the strongest association with receiving AUD treatment within 90 days afterward — stronger even than addiction psychiatry consultation or gastroenterology consultation [14]✓ Verified knowledgeThompson et al. (2017) — Drug therapy alcohol. Patients who received AUD treatment had improved transplant-free survival (HR 0.44, p=0.04) [14]✓ Verified knowledgeThompson et al. (2017) — Drug therapy alcohol.

What happens before discharge determines what happens after it. If you or a loved one is being discharged after an ALD-related hospitalization, asking directly about AUD medication and follow-up referrals before leaving is one of the most important things you can do. Alcohol rehab options range from outpatient support to residential programs, and the right level of care depends on the full clinical picture.

Are some people at higher risk for faster progression?

Women develop alcoholic liver disease at lower cumulative alcohol exposure than men — a phenomenon called telescoping, where the timeline from drinking to serious harm is compressed. Women with ALD tend to present at younger ages and with more advanced disease despite shorter drinking histories. Clinical concern should be triggered at lower thresholds.

People with metabolic overlap (MetALD) — those who carry both alcohol-associated liver disease and metabolic dysfunction-associated steatotic liver disease (MASLD) — face accelerated damage that neither a liver-only nor a metabolic-only approach fully addresses. Obesity, type 2 diabetes, and metabolic syndrome compound the alcohol-related injury.

People with hepatitis C co-infection face dramatically accelerated fibrosis progression and higher liver cancer risk. Direct-acting antiviral therapy is highly effective and should not be withheld from people with ALD — though active heavy drinking can affect adherence. Achieving HCV cure while continuing to drink does not eliminate the ALD risk.

People living with HIV face accelerated liver fibrosis through both direct viral effects and antiretroviral hepatotoxicity. Drug interactions between antiretrovirals and AUD medications require careful attention.

What's still unknown — and why it matters

Honest medicine requires naming the gaps. Several important questions remain unanswered:

• What's the best pharmacotherapy for acute alcoholic hepatitis beyond corticosteroids? The STOPAH trial established prednisolone's modest short-term benefit, but no agent has demonstrated sustained long-term improvement [2]✓ Verified knowledgeLee et al. (2024) — Designing clinical trials. G-CSF and other regenerative approaches are under investigation.

• Who exactly should qualify for early liver transplant? The evidence is growing, but the field lacks consensus on patient selection criteria and psychosocial assessment standards across programs.

• How long should AUD medications be continued in transplant candidates? The data show benefit with at least three months of use [6]✓ Verified knowledgeJophlin et al. (2024) — Acg clinical guideline, but optimal duration, agent selection, and monitoring protocols in the pre- and post-transplant periods aren't established.

• What happens in the first 72 hours after discharge? The evidence is largely silent on whether telephone follow-up, medication bridging, peer navigation, or warm handoffs affect the critical transition from inpatient crisis to outpatient engagement. This is an actionable gap.

These gaps don't undermine what is known. They point to where the next generation of research needs to go.